EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial

Maliazurina B Saad, Eman Showkatian, Vivek Verma, Qasem Al-Tashi, Muhammad Aminu, Xinyan Xu, Muhamed Qayati Mohamed, Morteza Salehjahromi, Sheeba J Sujit, Yuliya Kitsel, Steven H Lin, Zhongxing Liao und 10 weitere

Journal for ImmunoTherapy of Cancer · 2025

DOI: 10.1136/jitc-2025-013074 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2025. Verfasst von Maliazurina B Saad und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Immunotherapy, Radiosurgery. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, NCRR NIH HHS, National Cancer Institute at the National Institutes of Health through the Cancer Cen-ter Core.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The recent phase II randomized stereotactic ablative radiotherapy with and without immunotherapy (I-SABR) trial has shown improved event-free survival (EFS) when adding immunotherapy to stereotactic ablative radiotherapy (SABR) for early-stage inoperable non-small cell lung cancer (NSCLC). However, optimizing patient selection thereof is critical, because not every patient benefits from immunotherapy. Leveraging the powerful use of artificial intelligence, this secondary analysis of the I-SABR trial developed a modeling system (named “I-SABR-SELECT”) based on clinical and radiomic factors to address which patients should receive additional immunotherapy.

Methods

The discovery/validation cohorts were from the I-SABR trial, with external validation from the single-arm STARS trial. Individual treatment effect scores, estimating the benefit of adding immunotherapy, were derived from radiomic and clinical predictors using counterfactual reasoning. Dimensionality reduction was applied to mitigate overfitting and enhance model robustness. We also evaluated the average treatment effect between subgroups of patients who were treated following versus against the model’s recommendation.

Results

The model recommended that 49% (69/141) patients enrolled in the I-SABR trial switch treatments (65% (49/75) in the SABR arm and 30% (20/66) in the I-SABR arm). Patients treated by the model’s recommendation had higher EFS, with HRs of 0.06 (in the I-SABR arm, p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsImmunotherapyRadiosurgeryPatient SelectionArtificial IntelligenceHumansMaleFemaleNeoplasm StagingMiddle AgedAgedCombined Modality TherapyRadiomics

Stichwörter der Autor:innen

BiomarkerLung CancerRadiotherapy/radioimmunotherapyStatisticsSurvivorship

Autor:innen und Institutionen

  • Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Thoracic Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Institute of Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

Förderung

  • NCI NIH HHS
  • NCRR NIH HHS
  • National Cancer Institute at the National Institutes of Health through the Cancer Cen-ter Core
  • Clinical and Translational Science Award
  • Bristol-Myers Squibb and MD Anderson Cancer Center Alliance
  • Texas 4000 Distinguished Professorship at the MD Anderson Cancer Center and the Joan and Herb Kelleher Charitable Foundation

Zitieren

APA

Saad, M. B., Showkatian, E., Verma, V., Al-Tashi, Q., Aminu, M., Xu, X., Qayati Mohamed, M., Salehjahromi, M., Sujit, S. J., Kitsel, Y., Lin, S. H., Liao, Z., Gandhi, S., Qian, D., Jaffray, D., Chung, C., Vokes, N. I., Zhang, J., Lee, J. J., …, & Chang, J. Y. (2025). Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-013074

Vancouver

Saad MB, Showkatian E, Verma V, Al-Tashi Q, Aminu M, Xu X, et al. Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial. Journal for ImmunoTherapy of Cancer. 2025. doi:10.1136/jitc-2025-013074

BibTeX
@article{Saad2025,
  author = {Saad, Maliazurina B and Showkatian, Eman and Verma, Vivek and Al-Tashi, Qasem and Aminu, Muhammad and Xu, Xinyan and Qayati Mohamed, Muhamed and Salehjahromi, Morteza and Sujit, Sheeba J and Kitsel, Yuliya and Lin, Steven H and Liao, Zhongxing and Gandhi, Saumil and Qian, David and Jaffray, David and Chung, Caroline and Vokes, Natalie I and Zhang, Jianjun and Lee, J Jack and Heymach, John V and Wu, Jia and Chang, Joe Y},
  title = {Causal AI-based clinical and radiomic analysis for optimizing patient selection in combined immunotherapy and SABR in early-stage NSCLC: a secondary analysis of the phase II I-SABR trial},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2025},
  doi = {10.1136/jitc-2025-013074}
}
Kostenlos starten →